• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

BeiGene (Group)

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 7,700 colleagues across five continents. *

 

	Start	2013-05-31 existent
	Industry	B-Raf kinase inhibitor
	Industry 2	cancer drug
	Person	Oyler, John V. (BeiGene 201305 CEO + Co-Founder)
	Region	Beijing (Peking)
	Country	China
	Street	30 Science Park Road Zhongguancun Life Science Park, Changping District
	City	102206 Beijing
	Tel	+86-010-851 48500
		Address record changed: 2021-11-28
Basic data	Employees	G: 5,001 to 10,000 (2021-11-23)
	Currency	USD
	Annual sales	308,874,000 (revenues, total, consolidated (2020) 2020-12-31)
	Profit	-1,600,523,000 (2020-12-31)
	Cash	1,381,950,000 (2020-12-31)
		* Document for �About Section�: BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Launches Proposed Initial Public Offering on the STAR Market in China". Cambridge, MA & Beijing.
		Record changed: 2022-03-05

Advertisement

More documents for BeiGene (Group)

• [1] BeiGene, Ltd.. (7/13/22). "Press Release: BeiGene Appoints Chan Lee as General Counsel". Cambridge, MA, Basel & Beijing....
• [2] BeiGene, Ltd.. (5/17/22). "Press Release: BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland". Cambridge, MA, Basel & Beijing....
• [3] Celeris Therapeutics GmbH. (2/24/22). "Press Release: CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors". Menlo Park, CA....
• [4] Novartis AG. (12/20/21). "Press Release: Novartis Strengthens Immunotherapy Pipeline with Option, Collaboration and License Agreement with BeiGene for TIGIT inhibitor Ociperlimab". Basel....
• [5] BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center". Hopewell, NJ, Cambridge, MA & Beijing....
• [6] BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Launches Proposed Initial Public Offering on the STAR Market in China". Cambridge, MA & Beijing....
• [7] BeiGene, Ltd.. (11/23/21). "Press Release: BeiGene Announces Approval of Brukinsa (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia". Basel, Cambridge, MA & Beijing....
• [8] Novartis AG. (1/11/21). "Press Release: Novartis Expands Oncology Pipeline with In-licensing of Tislelizumab from BeiGene". Basel....
• [9] Strand Therapeutics Inc.. (1/11/21). "Press Release: Strand Therapeutics and BeiGene Enter into Agreement to Develop Solid Tumor Immuno-Oncology Therapeutics Based on Strand’s Next-Generation, Multi-Functional mRNA Technology". Cambridge, MA & Beijing....
• [10] BeiGene, Ltd.. (10/31/19). "Press Release: BeiGene Announces Global Strategic Oncology Collaboration with Amgen". Cambridge, MA & Beijing....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.